Diversified Trust Co Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Diversified Trust Co raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 7.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,803 shares of the biopharmaceutical company’s stock after buying an additional 5,170 shares during the quarter. Diversified Trust Co’s holdings in Amicus Therapeutics were worth $712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Comerica Bank boosted its holdings in shares of Amicus Therapeutics by 0.8% during the 4th quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 774 shares during the last quarter. Van ECK Associates Corp increased its stake in Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 873 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Amicus Therapeutics by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock worth $780,000 after acquiring an additional 1,258 shares in the last quarter. American International Group Inc. boosted its position in shares of Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after acquiring an additional 1,298 shares during the last quarter. Finally, Inspire Investing LLC grew its holdings in shares of Amicus Therapeutics by 12.4% in the first quarter. Inspire Investing LLC now owns 31,094 shares of the biopharmaceutical company’s stock valued at $366,000 after purchasing an additional 3,422 shares in the last quarter.

Amicus Therapeutics Trading Down 1.2 %

Shares of NASDAQ FOLD traded down $0.14 during trading hours on Wednesday, reaching $11.58. The stock had a trading volume of 254,873 shares, compared to its average volume of 2,854,833. The business’s fifty day moving average price is $10.27 and its two-hundred day moving average price is $11.05. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of -23.92 and a beta of 0.71. Amicus Therapeutics, Inc. has a 52-week low of $9.02 and a 52-week high of $14.57. The company has a current ratio of 3.03, a quick ratio of 2.61 and a debt-to-equity ratio of 2.97.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $126.67 million for the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The business’s revenue was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.15) EPS. Analysts expect that Amicus Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. UBS Group lowered their price objective on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Morgan Stanley decreased their price objective on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, May 10th. Wells Fargo & Company started coverage on Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective for the company. Finally, Guggenheim upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Tuesday, May 14th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.57.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.